CPT 90296: Diphtheria Antitoxin (Equine)
CPT code 90296 denotes diphtheria antitoxin, an equine-derived antitoxic serum used to prevent or treat diphtheria by neutralizing circulating toxin. Nationally, this code is relevant for acute care clinicians, hospital billing departments, and payers managing coverage for a rare but high-acuity intervention. The code captures administration of a biologic product that is typically used in inpatient or emergency settings where observation for hypersensitivity is required.
Key payers referenced in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the clinical indications and service context for 90296, plus a summary of payer coverage considerations and coding practice themes. The publication outlines typical sites of service, common billing modifiers provided in the input, and notes on where input data are incomplete.
This briefing is intended to provide national-level context: what the code represents, why it matters in acute care billing, and what billing teams and policy analysts should expect when encountering claims for equine diphtheria antitoxin. Data not available in the input are identified where applicable.
Sign up for cpt 90296 policy alerts
Get alerted when payer policies referencing 90296 are released or updated.
Billing Code Overview
CPT code 90296 represents diphtheria antitoxin, a sterile aqueous solution of refined and concentrated proteins (chiefly globulins) containing antitoxic antibodies derived from the blood serum of horses (equine) immunized against diphtheria toxin. The product is used to prevent or treat diphtheria by providing passive immunization to neutralize circulating toxin.
Service type: Antitoxin administration for treatment or prophylaxis of diphtheria.
Typical site of service: Hospital inpatient or emergency department, and other acute care settings where rapid administration of antitoxin and monitoring for adverse reactions are available.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and detailed service line information.
Clinical & Coding Specifications
Clinical Context
A 7-year-old child presents to the emergency department with a 24-hour history of progressive pharyngitis, fever, and a grayish pseudomembrane on the tonsils after travel to a region with low diphtheria immunization coverage. The emergency physician evaluates airway patency, obtains a throat culture and rapid swab, and in consultation with infectious disease and public health officials orders diphtheria antitoxin for immediate administration while awaiting confirmatory testing. The antitoxin is obtained from a regional public health stock, prepared by pharmacy under sterile conditions, and administered intravenously in monitored inpatient or ED observation settings with airway management and cardiac monitoring available due to risk of hypersensitivity and serum sickness.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | General reporting default (no modifier) | Use when no specific modifier applies and the service is billed as usual |
22 | Unusual procedural services | Use when administration required significantly greater effort or resources than typical (e.g., complex airway management concurrent with antitoxin administration) |
52 | Reduced services | Use when partial administration or reduced scope of service occurred (e.g., partial dose given due to reaction) |
53 | Discontinued procedure | Use when administration was started but stopped for patient safety (e.g., anaphylaxis) |
55 | Postoperative management only | Rare; use when only post-administration management is billed separately from the antitoxin supply |
56 | Preoperative management only | Rare; use when only pre-administration evaluation is billed separately |
SL | State or local vaccine program supplied vaccine/biological | Use when the diphtheria antitoxin is supplied by a state or local public health program and not purchased by the billing provider |
TC | Technical component | Use when billing only the technical component of a service related to preparation/administration when separable |
| Taxonomy Code | Specialty | Notes |
|---|---|---|
| 207RH0000X | Infectious Disease | Specialist consulted for diagnosis and antitoxin indication/dosing |
| 207L00000X | Emergency Medicine | ED physicians commonly initiate antitoxin administration and airway stabilization |
| 207K00000X | Pediatrics | Pediatricians manage children presenting with suspected diphtheria and coordinate inpatient care |
| 363A00000X | Clinical Laboratory | Laboratory specialists perform confirmatory microbiology testing and serology |
| 3336C0002X | Pharmacist | Clinical pharmacists prepare and verify antitoxin dosing and dilution |
Related CPT Codes
| CPT Code | Description | Relationship to This Procedure |
|---|---|---|
J0690 | Injection, immune globulin, (for example, intravenous IG), non-specific, 500 mg | May be used for supportive immune globulin therapy in severe toxin-mediated disease when indicated |
36415 | Collection of venous blood by venipuncture | Performed to obtain cultures, serology, and baseline labs before or after antitoxin administration |
87070 | Culture, bacterial, any other source, other than urine, aerobic and anaerobic; culture | Throat or tissue cultures for Corynebacterium diphtheriae to confirm diagnosis |
99223 | Initial hospital care, typically 70 minutes or more, per day, for the evaluation and management of a patient, admitted to the hospital | Used for initial inpatient admission and complex care when antitoxin administration requires hospitalization |
31500 | Intubation, endotracheal, emergency procedure | Performed when airway compromise from diphtheritic pseudomembrane requires airway protection during antitoxin therapy |
Related Diagnoses
| ICD-10 Code | Description | Clinical Relevance |
|---|---|---|
A36.0 | Diphtheria of nasal mucous membrane | Primary cause of diphtheria infection; indicates antitoxin use when toxin-mediated disease suspected |
A36.1 | Diphtheria of pharynx and tonsils | Common presentation requiring antitoxin to neutralize circulating toxin and prevent systemic complications |
A36.2 | Diphtheria of larynx and trachea | Airway-threatening disease where antitoxin and airway management are critical |
A36.3 | Diphtheria of other sites | Used when diphtheria affects atypical locations; antitoxin indicated for systemic toxin effects |
A36.8 | Other forms of diphtheria | Miscellaneous diphtheria diagnoses where antitoxin may be required |
A36.9 | Diphtheria, unspecified | Used when diphtheria is diagnosed but site not specified; antitoxin considered based on clinical severity |